An unprecedented view
of cancer.

On Target’s fluorescent markers bind to cancerous tissue, enabling surgeons to see the lesions as they operate.

A complete surgical resection is the most important objective of cancer surgery. Yet the methods currently used to identify malignant tissue are limited – skilled surgeons often rely on a suboptimal patchwork of pre-operative imaging and real time visual and tactile cues.

To date, there has been no reliable way for surgeons to assess the location and full extent of cancerous tissue while operating.

ON TARGET LABORATORIES’s fluorescent markers bind to cancerous tissue, enabling surgeons to see the cancerous lesions as they operate.

On Target Laboratories’s fluorescent markers are comprised of a near-infrared dye and a targeting molecule, or ligand that binds to the receptors overexpressed on cancer cells. These markers illuminate the cancerous lesions, literally lighting the way for the resection of malignant tissue.

On Target’s first novel compound OTL38 targets folate receptors commonly found on many cancers, including ovarian and lung.

This novel intraoperative marker is creating an entirely new category for precision in the surgical resection of cancer. The ultimate result — surgeons can feel even more confident in the pursuit of a more complete surgical resection for their patients.

How it Works

The compound is administered to the patient via IV infusion anytime between 1 to 24 hours prior to the procedure, as best fits the procedure workflow and patient needs.

With the help of a near-infrared camera, the surgeon is able to see malignant tissue during the operation. This illumination may enable various benefits, including

In Lung Cancer

Patients receive an IV infusion and with the help of a near-infrared camera, the surgeon is able to see cancerous lesions as they operate

Localization of primary lesion

Assessment of surgical margin

Identification of synchronous lesions

In Ovarian Cancer

Patients receive an IV infusion and with the help of a near-infrared camera, the surgeon is able to see cancerous lesions as they operate

Identification of additional cancerous lesions

Clinical trials are underway in more than a dozen centers to evaluate our portfolio of fluorescent markers. Clinical trials are underway in more than a dozen centers to evaluate our portfolio of fluorescent markers.

Development

We’re developing technology where it’s needed most.

Lung, ovarian, prostate, and colorectal cancers alone make up nearly 72% of inpatient oncology procedures in the US1. On Target is the first to bring intraoperative targeted fluorescent markers to lung and ovarian cancers, with more indications in our pipeline. The potential of this technology has us committed to expanding our portfolio and increasing the number of complete surgical resections for cancer patients.

1 Orosco, Ryan, et al. Positive Surgical Margins in the 10 Most Common Solid Cancers. Nature. 2018; 8:5686. doi:10.1038/s41598-018-23403-5

 

Clinical Research

Clinical trials are underway in more than a dozen centers to evaluate On Target Laboratories’s portfolio.

Ovarian Cancer Phase 3 Study

This study is to confirm the efficacy of OTL38 in combination with near-infrared fluorescence imaging to detect additional ovarian cancer lesions not detected by palpation and visualization under normal light during surgery

Learn More

Lung Cancer Phase 3 Study

This study aims to assess the efficacy, safety, and tolerability of OTL38 and near-infrared fluorescence imaging at identifying pulmonary nodules within the operating theater

Learn More

Prostate Cancer Phase 1/2a Study

This study is to assess the safety, tolerability and pharmacokinetics of OTL78, a PSMA-targeted fluorescent marker, for the intraoperative imaging of prostate cancer

Learn more
Brand Strategy By Assembly
Developed By Alchemy + Aim